Follicular Lymphoma

Follicular lymphoma is one of the most common kinds of non-Hodgkin lymphoma. Its progression rate varies widely, though it tends to spread slowly and has few symptoms. Patients with follicular lymphoma usually survive ten years or longer.

What is Follicular Lymphoma?

Follicular lymphoma is a cancer of the B-cells that accounts for around one third of all cases of lymphoma. The cancer is a form of non-Hodgkin lymphoma that usually affects adults, with an average age-at-diagnosis of 60. Follicular lymphoma is more common among women than among men.

Follicular Lymphoma Causes

Follicular Lymphoma Treatments

Relapsed/Refractory Follicular Lymphoma

Relapsed/Refractory Follicular Lymphoma Support

Relapsed/Refractory Follicular Lymphoma Prognosis and Epidemiology

Relapsed/Refractory Follicular Lymphoma Causes

Relapsed/Refractory Follicular Lymphoma Response Evaluation

Relapsed/Refractory Follicular Lymphoma and Personalized Medicine

Relapsed/Refractory Follicular Lymphoma Treatment

Latest Follicular Lymphoma News and Research

Evaluating a third SARS-CoV-2 mRNA vaccine in anti-CD20-treated patients

In a new study, researchers assessed the efficacy of a third dose of COVID-19 vaccine in anti-CD20 antibody-treated individuals.

4 May 2022

Study investigates recombinant SARS-CoV-2 variants in immunocompromised individuals

Researchers identified the recombination of two SARS-CoV-2 variants.

28 Mar 2022

New grant program launches to advance therapeutic discovery for follicular lymphoma

Today saw the launch of a dedicated grant program aimed at advancing therapeutic discovery for follicular lymphoma (FL), The Follicular Lymphoma Foundation (FLF) CURE FL Awards - Curative Research to Eliminate Follicular Lymphoma.

10 Jan 2022

Clinical studies show enhanced responses for lymphoma patients treated with axi-cel CAR T cell therapy

Three clinical studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated enhanced responses for patients with high-risk lymphoma treated with axicabtagene ciloleucel (axi-cel) chimeric antigen receptor (CAR) T cell therapy.

12 Dec 2021

International collaboration secures €1M grant to investigate new treatment target for lymphoma

An international collaboration involving researchers from Queen Mary University of London, Memorial Sloan Kettering Cancer Center, New York and Dana-Farber Cancer Institute, Boston has secured a €1M research grant from Dutch blood cancer charity, Lymph&Co, to investigate a new treatment target for lymphoma.

25 Nov 2021

Implications of persistent SARS-CoV-2 infection in patients with lymphoid malignancies

In a recent study, scientists attempt to understand persistent COVID-19 and its implications in patients with hematologic malignancies.

6 Sep 2021

New integrative NGS panel for analysis of standard and novel biomarkers in lymphoid neoplasms

Increasing knowledge about genomic biomarkers has facilitated better monitoring and personalized management of patients with B-cell malignant tumors.

29 Jul 2021

SwRI researchers part of two collaborative teams receive SAMF bioscience grants

Collaborative teams that include Southwest Research Institute staff received two of six recently awarded San Antonio Medical Foundation (SAMF) bioscience grants. SwRI, in collaboration with UT Health San Antonio and University Health System, received a nearly $200,000 grant to develop machine learning algorithms for cancer detection.

31 Mar 2021

Clinical trial shows five-year outcomes of CAR T-cell therapy for non-Hodgkin lymphomas

A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah, researchers in Penn's Abramson Cancer Center reported today in the New England Journal of Medicine.

18 Feb 2021

Prolonged shedding and multiple mutations 154 days after initial SARS-CoV-2 diagnosis reported

An interesting new preprint published on the medRxiv server describes an immunosuppressed patient with coronavirus disease 2019 (COVID-19) who continued to shed the virus for an astounding 154 days. During this period, the virus underwent numerous mutations.

19 Jan 2021

MDC researchers develop a potent weapon against lymphomas

MDC researchers have developed a new approach to CAR T-cell therapy. The team has shown in Nature Communications that the procedure is very effective, especially when it comes to fighting follicular lymphomas and chronic lymphocytic leukemia, the most common type of blood cancer in adults.

11 Jan 2021

Researchers evaluate safety of novel therapy for patients with non-Hodgkin lymphoma

Roswell Park Comprehensive Cancer Center's Francisco J. Hernandez-Ilizaliturri, MD, along with a team of researchers from other institutions, has been investigating a novel therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

7 Dec 2020

Study: CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial.

6 Dec 2020

More than 40 Dana-Farber studies to be presented at the virtual 62nd ASH Annual Meeting

Dana-Farber Cancer Institute researchers will present more than 40 research studies at the virtual 62nd American Society of Hematology Annual Meeting on December 5-8, including two studies that were selected for inclusion in the official press program.

1 Dec 2020

Yale and AI Therapeutics launch clinical trial of potential COVID-19 drug

Yale School of Medicine and the biopharmaceutical firm AI Therapeutics have launched a multi-institutional clinical trial of a drug for treating COVID-19.

27 Jul 2020

Combining two immunotherapies into a single treatment found to be more effective

Some of the most promising advances in cancer treatment have centered on immunotherapies that rev up a patient's immune system to attack cancer. But immunotherapies don't work in all patients, and researchers have been searching for ways to increase their effectiveness.

23 Jul 2020

Study shows potential new approach to treating two common subtypes of lymphoma

A study at The University of Texas MD Anderson Cancer Center demonstrated a potential new approach to treating two of the most common subtypes of lymphoma through manipulation of molecular programs controlled by the cAMP-response element binding protein.

8 Jan 2020

Next-generation sequencing can detect genetic alterations specific to follicular lymphoma

People with follicular lymphoma, a slow-growing lymphatic-system cancer, who have been treated and are in remission for at least two years, may no longer have what has been considered an incurable disease based on highly sensitive testing.

9 Dec 2019

$Experimental immunotherapy can put patients with relapsed or refractory lymphoma into remission$

Experimental immunotherapy can put patients with relapsed or refractory lymphoma into remission

A new, experimental immunotherapy can put patients with B-cell non-Hodgkin lymphoma (NHL) that is resistant to or has come back after multiple other therapies, including CAR T therapy, into remission.

8 Dec 2019

Cancer patients share survivorship story, celebrate strength and self-care

To survive in his struggle against an aggressive form of prostate cancer, Bin McLaurin didn't only have to overcome the disease attacking his body. He said he also had to toss out his long-held image of masculinity.

16 Jun 2019

Follicular Lymphoma

Overview

Follicular Lymphoma Causes

Follicular Lymphoma Treatments

Relapsed/Refractory Follicular Lymphoma

Feature Articles

Relapsed/Refractory Follicular Lymphoma

Relapsed/Refractory Follicular Lymphoma Support

Relapsed/Refractory Follicular Lymphoma Prognosis and Epidemiology

Relapsed/Refractory Follicular Lymphoma Causes

Relapsed/Refractory Follicular Lymphoma Response Evaluation

Relapsed/Refractory Follicular Lymphoma and Personalized Medicine

Relapsed/Refractory Follicular Lymphoma Treatment

Latest Follicular Lymphoma News and Research

Evaluating a third SARS-CoV-2 mRNA vaccine in anti-CD20-treated patients

Study investigates recombinant SARS-CoV-2 variants in immunocompromised individuals

New grant program launches to advance therapeutic discovery for follicular lymphoma

Clinical studies show enhanced responses for lymphoma patients treated with axi-cel CAR T cell therapy

International collaboration secures €1M grant to investigate new treatment target for lymphoma

Implications of persistent SARS-CoV-2 infection in patients with lymphoid malignancies

New integrative NGS panel for analysis of standard and novel biomarkers in lymphoid neoplasms

SwRI researchers part of two collaborative teams receive SAMF bioscience grants

Clinical trial shows five-year outcomes of CAR T-cell therapy for non-Hodgkin lymphomas

Prolonged shedding and multiple mutations 154 days after initial SARS-CoV-2 diagnosis reported

MDC researchers develop a potent weapon against lymphomas

Researchers evaluate safety of novel therapy for patients with non-Hodgkin lymphoma

Study: CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

More than 40 Dana-Farber studies to be presented at the virtual 62nd ASH Annual Meeting

Yale and AI Therapeutics launch clinical trial of potential COVID-19 drug

Combining two immunotherapies into a single treatment found to be more effective

Study shows potential new approach to treating two common subtypes of lymphoma

Next-generation sequencing can detect genetic alterations specific to follicular lymphoma

Experimental immunotherapy can put patients with relapsed or refractory lymphoma into remission

Cancer patients share survivorship story, celebrate strength and self-care

Using AI to save the lives of mothers and babies

Tracking a Pathogen through its Genome: the challenges and opportunities of the global governance of genomic surveillance

Mapping the Types and Traits of Immune Cells

Follicular Lymphoma

Overview

Feature Articles

Relapsed/Refractory Follicular Lymphoma

Relapsed/Refractory Follicular Lymphoma Support

Relapsed/Refractory Follicular Lymphoma Prognosis and Epidemiology

Relapsed/Refractory Follicular Lymphoma Causes

Relapsed/Refractory Follicular Lymphoma Response Evaluation

Relapsed/Refractory Follicular Lymphoma and Personalized Medicine

Relapsed/Refractory Follicular Lymphoma Treatment

Latest Follicular Lymphoma News and Research

Using AI to save the lives of mothers and babies

Tracking a Pathogen through its Genome: the challenges and opportunities of the global governance of genomic surveillance

Mapping the Types and Traits of Immune Cells

Newsletters you may be interested in